{"filings":[{"id":981957,"accession_number":"0001759138-26-000033","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2026-06-11T11:01:13+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Cabaletta Bio stockholders approve doubling authorized shares to 600M; re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 300M to 600M shares (80.4M for, 1.8M against).","Directors Scott Brun, M.D. and Shawn Tomasello, MBA re-elected as Class I directors to 3-year terms.","Ratified Ernst & Young LLP as independent auditor for FY 2026 (82.1M for).","Advisory say-on-pay passed with 27.5M for vs 26.0M against (broker non-votes 28.7M).","Proposal 3 (Plan Amendment) was withdrawn by Board before the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":815399,"accession_number":"0001759138-26-000030","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2026-06-03T11:02:06+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio reports positive rese-cel data at EULAR; registrational plans for SSc, DM/ASyS, JDM updated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["83% (5/6) DM patients achieved immunomodulator-free moderate/major TIS response at 16 weeks; all maintained through 1.5 years.","First two PC-free lupus patients: one achieved deep B cell depletion; PK/PD suggests lowest dose is threshold, enabling potential outpatient use.","SSc registrational study of ~25 patients with ILD to start 4Q26; primary endpoint FVC at 52 weeks.","DM/ASyS registrational cohort topline data expected mid-2027; JDM to be included in 2H27 BLA with potential priority review voucher.","Safety: no ICANS in myositis; 87% SSc patients no/grade1 CRS; 94% SLE preconditioning no/grade1 CRS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77482,"accession_number":"0001759138-26-000025","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2026-05-14T11:06:42+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cabaletta Bio Q1: R&D $37.4M, cash $116.6M; $150M equity raise; rese-cel advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses $37.4M (up 29% YoY); G&A $6.9M (down 15% YoY); cash $116.6M as of March 31, 2026.","Post-quarter $150M registered direct offering closed in May 2026, extends cash runway into mid-2027.","Preconditioning-free rese-cel data presented at ASGCT; lowest dose showed drug-free responses in 4 PV patients.","Registrational RESET-Myositis trial progressing with BLA submission planned for 2027; higher dose and longer-term data expected 2H26.","Entered 10-year commercial supply agreement with Cellares for automated manufacturing of rese-cel."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77443,"accession_number":"0001759138-26-000024","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2026-05-14T11:02:18+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio presents preconditioning-free clinical data and automated manufacturing data for rese-cel at ASGCT 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two of four pemphigus vulgaris patients at lowest PC-free dose maintained drug-free responses through 6 months.","No dose-limiting toxicities or neurotoxicity; one patient had grade 1 cytokine release syndrome.","First two autoimmune patients dosed with rese-cel manufactured on Cell Shuttle met all release specs with similar PK/PD.","Higher-dose PC-free data expected 2H26; initial SLE data at lowest dose expected 1H26 at EULAR 2026 Congress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95245,"accession_number":"0001193125-26-202446","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio prices $150M underwritten offering of 51.7M shares at $2.90; net proceeds ~$141M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["51,725,000 shares offered at $2.90; net proceeds ~$141M after underwriting discounts and expenses.","Offering includes participation from Bain Capital Life Sciences, Adage Capital, Cormorant Asset Management, and Eli Lilly.","Preliminary cash & equivalents as of March 31, 2026: $117M.","Net proceeds to fund expanded clinical development of rese-cel (myositis registrational study and additional indications) and manufacturing for commercial readiness.","Company expects cash runway into mid-2027 based on current operating plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95244,"accession_number":"0001193125-26-202389","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cabaletta Bio reports rese-cel activity without preconditioning in 4 PV patients; ASGCT presentation May 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2 of 4 refractory PV patients on rese-cel at lowest dose showed compelling clinical activity through 6 months without preconditioning.","Complete peripheral B-cell elimination observed in 3 of 4 patients; 3 of 4 remained off all immunomodulators and steroids as of April 2, 2026.","Safety: 1 of 4 patients had Grade 1 CRS; no ICANS of any grade. Additional patients enrolled at higher dose in RESET-PV.","RESET-SLE trial initial dose cohort (no preconditioning) fully enrolled; initial data expected first half 2026.","Data to be presented at ASGCT 2026 Annual Meeting on May 14, 2026; higher dose durability data anticipated H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95243,"accession_number":"0001759138-26-000016","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cabaletta Bio posts updated corporate presentation; no specific updates extracted from filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation posted to company website on April 20, 2026.","Presentation filed as an exhibit to Form 8-K; full content not provided in the excerpt.","Investors directed to www.cabalettabio.com for full presentation.","No material changes or new data identifiable from the available filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108165,"accession_number":"0001759138-26-000010","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cabaletta Bio Q4/FY2025 cash $133.6M; myositis BLA on track for 2027; $30M raise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 R&D expenses $36.2M, FY R&D $142.7M; cash $133.6M as of Dec 31, 2025; raised additional $30M in Q1 2026.","Registrational DM/ASyS cohort enrolling (17 patients); BLA submission for rese-cel in myositis targeted for 2027.","No-preconditioning rese-cel data from RESET-SLE expected 1H26 (initial) and 2H26 (durability); PV durability data throughout 2026.","Automated manufacturing with Cellares: initial clinical data expected 1H26; potential to produce for thousands per year.","Complete Phase 1/2 data from RESET-SSc, RESET-SLE, RESET-MG to be presented in 1H26; design updates for SSc in 1H26 and MG mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108164,"accession_number":"0001193125-26-009819","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta announces 2026 priorities: myositis trial enrolling, BLA 2027, Cellares IND cleared","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Myositis registrational cohort actively enrolling; BLA submission for rese-cel projected in 2027.","FDA aligned on registrational cohort designs in SLE and LN, each ~25 patients with unique endpoints.","FDA granted RMAT designation for rese-cel in systemic sclerosis; registrational alignment expected 1H26.","IND amendment cleared for Cellares automated manufacturing; clinical manufacturing data due 1H26.","No-preconditioning dose-escalation in PV ongoing; Phase 1/2 data from 3 trials expected 1H26."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124594,"accession_number":"0001193125-25-273272","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cabaletta Bio Q3 2025 R&D expenses $39.8M; rese-cel BLA submission targeted for 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses of $39.8M in Q3 2025, up from $26.3M a year ago; cash $159.9M as of Sep 30, 2025.","Myositis registrational cohort (14 patients) set to begin enrollment by year-end 2025; BLA submission planned for 2027.","FDA alignment on registrational cohort designs for SSc and SLE trials expected by year-end 2025.","EMA granted PRIME designation for rese-cel in myositis; FDA granted RMAT for SLE/LN and Fast Track for gMG.","Steve Gavel appointed Chief Commercial Officer; led CARVYKTI launch at Legend Biotech."],"consensus_eps_estimate":-0.4814,"consensus_eps_actual":-1.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124593,"accession_number":"0001193125-25-254610","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cabaletta Bio posts corporate presentation; no material updates evident from filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted to investors section of website on Oct 29, 2025.","Exhibit 99.1 text is truncated; specific clinical or financial updates not available.","No earnings, guidance, or operational changes indicated in the filing text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124592,"accession_number":"0001193125-25-250676","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio: all DM/ASyS myositis patients meet registrational endpoint; SSc and lupus data positive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 4 DM/ASyS patients with sufficient follow-up achieved immunomodulatory-free moderate or major TIS response at week 16.","Initiating DM/ASyS registrational cohort this quarter; plans 14 patients with 16-week primary endpoint of moderate or major TIS.","All 4 SSc patients with at least 3 months follow-up achieved rCRISS-25 response off all immunomodulators and steroids.","7 of 8 lupus patients with sufficient follow-up achieved DORIS remission or renal response; all 9 patients off immunomodulators.","Expanding RESET-SLE to include no preconditioning cohort; initial data expected 2026; 76 patients enrolled at 77 sites globally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124591,"accession_number":"0001193125-25-235533","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio presents first rese-cel data without preconditioning at ESGCT 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rese-cel without preconditioning achieved complete B cell depletion in two of three PV patients, with rapid autoantibody reduction and near-complete symptom resolution.","PDAI activity scores improved from baseline to latest follow-up: Patient 1 (24 to 10 at 4 mo), Patient 2 (83 to 3 at 3 mo), Patient 3 (22 to 2 at 1 mo).","All three patients remained off immunomodulators since infusion and are off or tapering steroids as of the September 11, 2025 data cut-off.","CAR T cell expansion kinetics without preconditioning were similar to those observed across 30+ patients dosed with preconditioning in other RESET trials.","No ICANS was reported; one patient had transient grade 1 CRS, and another required steroids for a disease flare that later tapered below baseline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141265,"accession_number":"0001759138-25-000007","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cabaletta Bio posts updated corporate presentation; full content not provided.","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["On September 3, 2025, Cabaletta posted an updated corporate presentation on its website.","The presentation was furnished as Exhibit 99.1 but appears truncated, lacking substantive data or new guidance.","No specific financial results, pipeline updates, or material changes were discernible from the filing.","The disclosure is routine Regulation FD, not a material event with quantitative details.","Investors should refer to the full presentation on the company's website for any updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141264,"accession_number":"0000950170-25-104570","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cabaletta Bio Q2 2025 R&D expenses $37.6M, cash $194.7M; myositis registrational cohort on track for 2H25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses $37.6M (vs $23.4M in Q2 2024); G&A $8.3M (vs $6.9M).","Cash, cash equivalents & short-term investments $194.7M as of June 30, 2025; runway into 2H26.","Closed $100M public offering (net ~$94M) in June 2025 to support rese-cel development and commercial readiness.","Myositis registrational cohort enrollment on track for 2H25; first BLA submission for rese-cel anticipated in 2027.","FDA meetings planned for lupus (3Q25), scleroderma (4Q25), and myasthenia gravis (1H26) registrational designs."],"consensus_eps_estimate":-0.6627,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159074,"accession_number":"0001193125-25-139517","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio prices $100M public offering of common stock and warrants to fund rese-cel development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 39.2M shares and 50M warrants at combined price of $2.00 per unit; net proceeds ~$94M.","Also offers 10.8M pre-funded warrants at $1.99999 per unit for certain investors.","Underwriters have 30-day option to purchase up to an additional 15M shares and/or warrants.","Proceeds to fund expanded clinical development of rese-cel, including potential registrational studies, and manufacturing readiness.","Cash runway expected into second half of 2026 based on current operating plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159073,"accession_number":"0001193125-25-138737","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["1.02","7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio reports strong rese-cel efficacy data in myositis, SLE, and scleroderma at EULAR 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["7 of 8 myositis patients achieved clinical response off all immunomodulators; all 4 ASyS/DM patients achieved meaningful TIS response.","All 7 SLE patients achieved clinical response off immunomodulators and glucocorticoids; all non-renal SLE patients achieved DORIS.","Both scleroderma patients showed meaningful mRSS improvements after discontinuing all immunomodulators and steroids, sustained to 6 months.","In 18 patients with ≥4 weeks follow-up, 94% had no or Grade 1 CRS; 89% had no ICANS; enrollment accelerated to 51 patients actively enrolled.","Company terminated ATM program with TD Cowen; prior sales of ~2.6M shares for $7.9M gross proceeds; $192M unused capacity cancelled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159072,"accession_number":"0001193125-25-137954","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Cabaletta Bio stockholders approve doubling authorized common shares to 300M, elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized shares increased from 150M to 300M; approved by 32.6M for vs 2.0M against.","Steven Nichtberger, M.D. and Mark Simon, MBA re-elected as Class III directors through 2028.","Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 31, 2025.","Say-on-pay approved with 52% support; stockholders selected annual frequency for future advisory votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159071,"accession_number":"0000950170-25-074589","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cabaletta Bio reprices underwater employee stock options to $1.92 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repricing effective May 19, 2025; applies to options with exercise price >1.5x May 19 closing price.","New exercise price set at $1.92; repriced options subject to a one-year retention period.","Approximately 75% of employee/director/consultant stock options were underwater before repricing.","Eligible participants include CEO Steven Nichtberger, CFO Anup Marda, and other executives/directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159070,"accession_number":"0000950170-25-071966","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cabaletta Bio to file BLA for rese-cel in myositis in 2027 after FDA alignment; cash $131.8M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA aligned on two registrational cohorts for rese-cel in myositis (~15 patients each, 26-week primary endpoint); BLA submission expected in 2027.","RMAT designation granted for rese-cel in myositis, enabling Fast Track/Breakthrough benefits and expedited BLA review.","Cash and equivalents $131.8M at March 31, 2025, down from $164M at Dec 31, 2024; funding into first half 2026.","FDA registrational discussions for SLE/LN anticipated in 3Q25; for systemic sclerosis in 4Q25.","Three oral presentations of rese-cel data in myositis, SLE/LN, and systemic sclerosis at EULAR 2025 in June."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177519,"accession_number":"0000950170-25-047196","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cabaletta Bio Q4/FY2024 results: cash $164M, R&D spend up, protocol deviation in SSc trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $164M as of Dec 31, 2024, providing runway into first half of 2026.","R&D expenses for FY2024 were $97.2M, up from $55.4M in FY2023.","Enrolled 33 patients across RESET program as of Mar 14, 2025; FDA meeting on myositis trial designs on track for 1H25.","Protocol deviation in RESET-SSc: patient infused with fever developed grade 3 ICANS; IDMC recommended trial continue.","Expanded CDMO agreement with Lonza for rese-cel clinical product supply starting 2H25."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177518,"accession_number":"0001193125-25-028143","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio: rese-cel shows deepening responses; 3/4 SLE in remission, first LN complete renal response","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3 of 4 non-renal SLE patients achieved DORIS remission; first LN patient achieved complete renal response; all 6 SLE/LN patients off immunosuppressants and steroids.","First dermatomyositis patient maintained major TIS improvement at 3 months off all therapies; IMNM patients showed more gradual improvement.","First SSc patient showed skin improvements and lung function improvement at 3 months post-infusion off disease-specific therapies.","Safety: 90% of first 10 patients had no or Grade 1 CRS; 90% had no ICANS. Deep B cell depletion confirmed via lymph node biopsy.","Enrollment: 50 clinical sites actively recruiting; 26 patients enrolled as of Feb 13, 2025; plan to meet FDA in H1 2025 on registrational design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177516,"accession_number":"0001193125-25-028420","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K/A","filed_at":"2025-02-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta reports deepened rese-cel responses: 3 SLE patients in DORIS remission, LN complete renal response","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3 of 4 non-renal SLE patients achieved DORIS remission; first LN patient achieved complete renal response; all off immunosuppressants and steroids.","First adult dermatomyositis patient maintained major TIS improvement at 3 months, off immunosuppressants and tapering steroids.","Safety: 90% had no CRS or Grade 1 CRS; 90% had no ICANS across first 10 patients dosed with rese-cel.","Deep B cell depletion within first month; repopulation with naïve phenotype starting ~2 months post-infusion; tissue depletion confirmed by lymph node biopsy.","50 clinical sites recruiting in US/Europe; 26 patients enrolled across RESET program as of Feb 13, 2025; average 1 patient/week since November."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177517,"accession_number":"0001193125-25-005016","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio reports $164M cash, expands rese-cel trials into MS, MG, PV; FDA meeting planned 1H25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Unaudited cash $164M as of Dec 31, 2024; funds operations into H1 2026.","21 patients enrolled across 44 RESET sites in US/Europe; safety data: 90% no CRS/grade 1, 90% no ICANS.","First patients enrolled in RESET-PV (no preconditioning) and RESET-MG; RESET-MS IND cleared with Fast Track.","Expanded CDMO agreement with Lonza for clinical supply from H2 2025.","Plans to meet FDA in 1H 2025 to align on registrational trial designs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194236,"accession_number":"0001193125-24-260425","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio reports positive CABA-201 data at ACR 2024; all 8 patients drug-free responses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eight patients dosed across RESET-Myositis, -SLE, -SSc trials; all off immunosuppressants through follow-up.","Favorable safety: no ICANS (except one prior LN case); low-grade CRS in 3/8, no tocilizumab needed.","Complete B cell depletion by day 22; transitional naïve B cell repopulation as early as 8 weeks in first 2 patients.","All 4 SLE patients showed clinical responses; LN patient proteinuria improved >90%. DM patient achieved major TIS response and normal muscle strength."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194235,"accession_number":"0000950170-24-126731","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cabaletta Bio Q3 2024: cash $183M, 40 U.S. sites recruiting; EMA greenlights lupus trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses $26.3M (up 91% YoY); G&A $6.8M (up 39%); cash $183.0M expected to fund ops into H1 2026.","16 patients enrolled, 10 dosed across RESET program as of Nov 12; 40 U.S. clinical sites actively recruiting.","EMA allowed CTA for RESET-SLE trial in Europe; myositis, lupus, scleroderma data presented at ACR weekend.","Gerwin Winter appointed SVP Head of International; Nicolette Sherman named CHRO replacing retiring Martha O'Connor.","Investor call Nov 18 to review ACR data; Jefferies London conference Nov 20."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194234,"accession_number":"0001193125-24-233294","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio provides updated clinical milestones: RESET data at ACR 2024, MG data H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Additional clinical data from RESET-SLE and RESET-Myositis trials to be presented at ACR Convergence 2024 in November.","Initial clinical data from the RESET-SSc trial also scheduled for ACR Convergence 2024.","Initial clinical data from the RESET-MG trial anticipated in the first half of 2025.","Updated corporate presentation posted on the company website with these milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210564,"accession_number":"0000950170-24-110389","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Cabaletta Bio amends lease with CIC; $5.5M aggregate rent over Initial Term","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease Amendment effective Oct 1, 2024 with CIC Innovation Communities.","Neither party may terminate office/lab space from Oct 2024 through Aug 2026 (Initial Term) except by mutual agreement or CIC breach/bankruptcy.","Company granted option to extend Initial Term by two additional 18-month terms.","Aggregate monthly rent approx. $240,000; total $5.5M over Initial Term.","Prior 30-day (office) and 90-day (lab) termination rights suspended during Initial Term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210563,"accession_number":"0001193125-24-196467","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cabaletta Bio Q2: $203.2M cash, 9 patients enrolled, Grade 4 ICANS DLT resolved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["R&D expenses $23.4M (Q2 2023: $11.8M); G&A $6.9M (Q2 2023: $4.1M).","Cash, equivalents and ST investments $203.2M, expected to fund ops into H1 2026.","Nine patients enrolled across RESET program as of Aug 5; 22 U.S. sites now active.","LN patient with active refractory disease had Grade 4 ICANS DLT; IDMC recommended study proceed at current dose.","New Lonza CDMO agreement and expanded Cellares partnership for CABA-201 manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228891,"accession_number":"0001193125-24-161089","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CABA-201 shows no CRS/ICANS/SAEs in first two patients; B cell depletion and disease score improvements observed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient in IMNM cohort had creatinine kinase drop from 617 to 308 and TIS of 30 at week 12.","First SLE patient had SLEDAI-2K score drop from 26 to 10 at week 4.","Complete B cell depletion by day 15 post-infusion; immature naïve B cell repopulation seen at week 8 in IMNM patient.","All chronic maintenance therapies discontinued for both patients except planned prednisone taper for SLE patient.","18 sites open, 5 patients enrolled as of June 12, 2024; initial data support current dose of 1e6 cells/kg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228890,"accession_number":"0001193125-24-154309","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cabaletta Bio 2024 annual meeting: Bollard and Henriques elected as directors, EY ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Catherine Bollard and Richard Henriques as Class II directors; Bollard received 26,225,488 for, 12,001,379 withheld; Henriques received 37,806,806 for, 433,474 withheld.","Ratification of Ernst & Young LLP as independent auditor for FY2024 passed with 41,355,429 for, 38,098 against, 5,728 abstain.","46,804,820 shares were outstanding as of the April 4, 2024 record date; no other matters voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228889,"accession_number":"0001193125-24-138874","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","2.01","7.01","9.01"],"status":"ready","headline":"Cabaletta Q1 2024: $223.8M cash, no CRS/ICANS in CABA-201 trials; clinical data at EULAR June","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and short-term investments of $223.8M as of March 31, 2024, down from $241.2M Dec 31, 2023; runway into H1 2026.","R&D expense $22.0M (vs $12.4M YoY); G&A $6.1M (vs $4.5M YoY).","No CRS or ICANS of any grade observed in first patients dosed in RESET-Myositis and RESET-SLE trials.","Initial clinical data from first patients in myositis and SLE to be presented at EULAR 2024 Congress in June.","FDA granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations for CABA-201 in myositis; Fast Track and Orphan for SSc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247527,"accession_number":"0001193125-24-073294","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cabaletta Bio reports Q4/FY2023 financials; first patient dosed with CABA-201 in myositis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments $241.2M as of Dec 31, 2023, with runway into 1H26.","R&D expenses $17.4M (Q4) and $55.4M (FY2023); G&A $5.7M (Q4) and $19.2M (FY2023).","First patient dosed in Phase 1/2 RESET-Myositis trial; no CRS or ICANS observed in first 21 days.","Initial clinical data from RESET-Myositis and RESET-SLE expected in 1H24; longer-term follow-up in 2H24.","FDA granted Rare Pediatric Disease designation for CABA-201 in juvenile dermatomyositis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247526,"accession_number":"0001193125-24-072048","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cabaletta Bio receives FDA Orphan Drug Designation for CABA-201 in systemic sclerosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants Orphan Drug Designation to CABA-201 for systemic sclerosis, a rare autoimmune disease.","CABA-201 is a fully human CD19-CAR T cell therapy being studied in Phase 1/2 RESET-SSc trial.","ODD provides tax credits, waived user fees, and potential 7-year marketing exclusivity upon approval.","Systemic sclerosis affects <200,000 US patients; average survival ~12 years after diagnosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247525,"accession_number":"0001193125-24-021894","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio receives FDA Orphan Drug Designation for CABA-201 in myositis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants Orphan Drug Designation to CABA-201, a CD19-CAR T cell therapy, for idiopathic inflammatory myopathies (myositis).","CABA-201 is being evaluated in the Phase 1/2 RESET-Myositis trial across three subtypes: DM, ASyS, and IMNM.","Orphan Drug Designation provides tax credits, fee waivers, and potential 7-year marketing exclusivity upon approval.","Myositis affects about 66,000 US patients; no curative therapy exists, with current treatments showing limited efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247524,"accession_number":"0001193125-24-003872","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"FDA grants Fast Track to CABA-201 for dermatomyositis and systemic sclerosis; cash $241M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Fast Track Designations for CABA-201 in dermatomyositis (improve disease activity) and systemic sclerosis (improve organ dysfunction).","Unaudited cash, cash equivalents and short-term investments of $241M as of Dec 31, 2023; cash runway into first half of 2026.","Raised ~$94.1M in Q4 2023 via ATM program at avg $19.76/share (4.76M shares).","Anticipates initial Phase 1/2 data for SLE and myositis in H1 2024; for SSc and gMG in H2 2024.","Plans to file INDs for CABA-201 in additional autoimmune indications in 2024; combined US prevalence >1M patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264987,"accession_number":"0001193125-23-274053","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","2.01","7.01","9.01"],"status":"ready","headline":"Cabaletta Bio Q3 2023 cash $164.4M; CABA-201 data expected H1 2024; IND clearances for SSc and gMG","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments of $164.4M as of Sept 30, 2023, up from $106.5M at Dec 31, 2022.","R&D expenses $13.8M (vs $8.2M in Q3 2022); G&A expenses $4.9M (vs $3.6M).","Initial clinical data from CABA-201 Phase 1/2 trials in lupus and/or myositis expected in first half of 2024.","IND clearances received for CABA-201 in systemic sclerosis (SSc) and generalized myasthenia gravis (gMG).","WuXi ATU selected as GMP manufacturing partner; Oxford Biomedica as lentiviral vector supplier for CABA-201."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264986,"accession_number":"0001193125-23-270840","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio receives FDA clearance for fourth CABA-201 IND, now in generalized myasthenia gravis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for CABA-201 in generalized MG; fourth IND across autoimmune diseases.","Phase 1/2 trial to enroll 12 patients in two parallel cohorts: AChR+ (n=6) and AChR- (n=6).","Starting dose remains 1 x 10^6 cells/kg, consistent with lupus, myositis, and systemic sclerosis trials.","gMG affects ~85% of an estimated 50,000-80,000 MG patients in the U.S.","Company expects initial clinical data from lupus/myositis trials in H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264985,"accession_number":"0001193125-23-248186","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio receives FDA clearance for third CABA-201 IND, now in systemic sclerosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Third IND clearance for CABA-201 (CD19-CAR T) in systemic sclerosis within past 6 months.","Phase 1/2 trial to enroll two parallel cohorts: severe skin (n=6) and severe organ involvement (n=6).","Starting dose 1×10^6 cells/kg, same as lupus and myositis trials; three-month data expected by H1 2024.","SSc affects ~88,000 US patients; average survival ~12 years after diagnosis with limited treatments.","Trial part of CARTA strategy aiming to reset immune system via transient B-cell elimination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282172,"accession_number":"0001193125-23-228144","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cabaletta Bio posts updated corporate presentation; content not fully provided in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Cabaletta Bio posted an updated corporate presentation to its investor website on September 5, 2023.","The presentation was filed as Exhibit 99.1, but only the disclaimer section is included in the provided text.","No material updates regarding pipeline, financials, or strategy can be confirmed from the filing excerpt.","Investors should refer to the full presentation on the company's website for potential updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282171,"accession_number":"0001193125-23-217481","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio and WuXi ATU expand GMP manufacturing for CABA-201; dedicated suite for commercial readiness","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WuXi ATU to provide GMP manufacturing for CABA-201, including commercial readiness, under expanded work orders.","Dedicated suite added for CABA-201 and MuSK-CAART programs; initial 18-month term with two 18-month extensions at Cabaletta's option.","Termination fee revised to $1.08M if both programs terminated; Cabaletta can terminate with 6 months' notice.","Expansion supports planned parallel Phase 1/2 trials in SLE and myositis, plus potential late-stage trials.","Cabaletta cites capital-efficient manufacturing strategy and prior successful collaboration with WuXi ATU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282170,"accession_number":"0001193125-23-208095","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cabaletta Bio Q2 2023: cash $176.3M; IND cleared for CABA-201 in myositis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents & investments of $176.3M as of June 30, 2023, extending runway into Q4 2025.","Net proceeds of ~$93.8M from May 2023 public offering of 8,337,500 shares at $12.00/share.","R&D expenses $11.8M (Q2 2023) vs $9.5M (Q2 2022); G&A $4.1M vs $3.5M.","FDA cleared second IND for CABA-201 in myositis; Fast Track designation granted for SLE/LN.","Anticipates initial 3-month clinical data for CABA-201 by first half of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282169,"accession_number":"0001193125-23-191895","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta appoints ex-Kite Pharma CCO Shawn Tomasello to board; updates DSG3-CAART data","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shawn Tomasello, former Kite Pharma CCO, appointed to board effective July 21, 2023.","Tomasello granted option for 44,000 shares at $13.48, vesting quarterly over three years.","DSG3-CAART combination sub-study shows modestly increased persistence with cyclophosphamide pretreatment.","New DSG3-CAART cohort initiated adding fludarabine to regimen to improve engraftment.","Company reiterates guidance for CABA-201 3-month clinical data by first half of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301300,"accession_number":"0001193125-23-158936","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Cabaletta Bio stockholders approve 3M share increase to 2019 equity plan, elect Scott Brun as director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scott Brun, M.D. elected Class I director with 23.6M votes for, 1.2M withheld, serving until 2026 annual meeting.","Amendment to 2019 Stock Option Plan approved, increasing authorized shares by 3,000,000 to 5,342,288.","Ratification of Ernst & Young as independent auditor for FY2023 passed with 27.3M votes for.","All proposals passed at June 1, 2023 Annual Meeting; no other matters voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301299,"accession_number":"0001193125-23-150530","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cabaletta Bio closes $100M public offering of 8.34M shares at $12.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $100 million from sale of 8,337,500 shares, including full exercise of underwriters' option for 1,087,500 additional shares.","Price of shares was $12.00 per share, before underwriting discounts and commissions.","Joint book-running managers: TD Cowen, Evercore ISI, Guggenheim Securities; lead manager H.C. Wainwright & Co.","Company expects net proceeds plus existing cash to fund operations into Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301298,"accession_number":"0001193125-23-148212","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cabaletta Bio prices $87M public offering of 7.25M shares at $12.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 7,250,000 shares at $12.00 per share; gross proceeds expected $87M before expenses.","Underwriters granted 30-day option for up to an additional 1,087,500 shares.","Net proceeds estimated at $81.18M after underwriting discounts and offering expenses.","Proceeds to fund expanded clinical development of CABA-201, manufacturing, and CAART programs.","Offering expected to close May 22, 2023; TD Cowen, Evercore ISI, Guggenheim lead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301297,"accession_number":"0001193125-23-146067","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA clears CABA-201 IND for Phase 1/2 myositis study; DesCAARTes updates provided","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared second IND for CABA-201 (CD19-CAR T) for Phase 1/2 trial in active myositis (DM, ASyS, IMNM) at 1x10^6 cells/kg dose.","Company plans to enroll 18 patients in three parallel cohorts (6 each) for dermatomyositis, anti-synthetase syndrome, and immune-mediated necrotizing myopathy.","DesCAARTes trial: modest persistence increase in first two patients in IVIg+Cy combination cohort; new fludarabine+IVIg+Cy cohort to be initiated.","MusCAARTes study timelines being evaluated based on emerging DesCAARTes data.","Myositis subtypes targeted affect ~66,000 patients in the US; current treatments often refractory."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301296,"accession_number":"0001193125-23-145622","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cabaletta Bio receives FDA clearance for second CABA-201 IND, Phase 1/2 trial in myositis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for CABA-201 in active idiopathic inflammatory myopathy (myositis); second IND clearance within two months.","Phase 1/2 trial to enroll 18 patients across three subtypes: dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy.","Initial dose 1 x 10^6 cells/kg, informed by preclinical data and Lancet Rheumatology publication.","Myositis subtypes impact ~66,000 patients in US; current treatments often inadequate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301295,"accession_number":"0001193125-23-141371","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cabaletta Bio Q1 2023: R&D spend $12.4M; CABA-201 IND cleared, Fast Track granted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses $12.4M (Q1 2023) vs $9.2M (Q1 2022); G&A $4.5M vs $3.8M.","Cash and equivalents $93.8M as of March 31, 2023; runway into Q1 2025.","FDA cleared IND for CABA-201 Phase 1/2 trial in lupus nephritis and SLE; Fast Track Designation granted.","Trial to enroll 6 LN and 6 SLE patients at 1.0x10^6 cells/kg; three-month efficacy data expected H1 2024.","Preclinical and updated DSG3-CAART data to be presented at ASGCT 26th Annual Meeting May 16-20."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301294,"accession_number":"0001193125-23-132565","cik":1759138,"company_name":"Cabaletta Bio, Inc.","ticker":"CABA","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cabaletta to present CABA-201 preclinical data and DSG3-CAART update at ASGCT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oral presentation on CD19 CAR T for SLE by CSO Samik Basu at ASGCT on May 16.","New preclinical data for CABA-201 (CD19 CAR T) shows comparable activity to FMC63 construct.","Updated DSG3-CAART clinical data shows enhanced persistence with IVIG/cyclophosphamide preconditioning.","Poster presentations on May 18 and 19; abstracts published on ASGCT website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":636728959.3342036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-05-02T23:59:59+00:00|301294"}